Taylor, Joseph J. http://orcid.org/0000-0002-9185-0427
Lin, Christopher http://orcid.org/0000-0003-2428-9980
Talmasov, Daniel http://orcid.org/0000-0002-4179-1713
Ferguson, Michael A.
Schaper, Frederic L. W. V. J. http://orcid.org/0000-0001-5487-0923
Jiang, Jing
Goodkind, Madeleine
Grafman, Jordan http://orcid.org/0000-0001-8645-4457
Etkin, Amit
Siddiqi, Shan H.
Fox, Michael D. http://orcid.org/0000-0001-8848-6399
Funding for this research was provided by:
Brain and Behavior Research Foundation (31081, 29441)
Sidney R. Baer, Jr. Foundation
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (K23MH129829, R01MH113929, K23MH121657, NIMH R21MH126271, R01MH113929, R21MH126271, R56AG069086, R01MH115949, R01AG060987)
American Epilepsy Society (846534)
Brain and Behavior Research Foundation
Brain and Behavior Research Foundation
U.S. Department of Veterans Affairs (I01 CX002293)
Neuronetics investigator-initiated grant
Nancy Lurie Marks Foundation Kaye Family Research Endowment
Article History
Received: 23 May 2022
Accepted: 23 November 2022
First Online: 12 January 2023
Competing interests
: J.J.T.: none. C.L.: none. D.T.: none. M.A.F.: none. F.L.W.V.J.S.: none. J.J.: none. M.G.: none. J.G.: none. A.E.: salary and equity from Alto Neuroscience, and equity from Mindstrong Health and Akili Interactive. S.H.S.: owner of intellectual property involving the use of brain connectivity to target TMS, scientific consultant for Magnus Medical, investigator-initiated research funding from Neuronetics and Brainsway, speaking fees from Brainsway and Otsuka (for PsychU.org), shareholder in Brainsway (publicly traded) and Magnus Medical (not publicly traded). None of these entities were directly involved in the present work. M.D.F.: scientific consultant for Magnus Medical, owner of independent intellectual property involving the use of functional connectivity to target TMS. This intellectual property was not used in the present manuscript.